Skip to main content

Main menu

  • Home
  • Our journals
    • Clinical Medicine
    • Future Healthcare Journal
  • Subject collections
  • About the RCP
  • Contact us

Clinical Medicine Journal

  • ClinMed Home
  • Content
    • Current
    • Ahead of print
    • Archive
  • Author guidance
    • Instructions for authors
    • Submit online
  • About ClinMed
    • Scope
    • Editorial board
    • Policies
    • Information for reviewers
    • Advertising

User menu

  • Log in

Search

  • Advanced search
RCP Journals
Home
  • Log in
  • Home
  • Our journals
    • Clinical Medicine
    • Future Healthcare Journal
  • Subject collections
  • About the RCP
  • Contact us
Advanced

Clinical Medicine Journal

clinmedicine Logo
  • ClinMed Home
  • Content
    • Current
    • Ahead of print
    • Archive
  • Author guidance
    • Instructions for authors
    • Submit online
  • About ClinMed
    • Scope
    • Editorial board
    • Policies
    • Information for reviewers
    • Advertising

Cavitating pulmonary tuberculosis: a global challenge

G Bothamley, M Lipman and O M Kon
Download PDF
DOI: https://doi.org/10.7861/clinmedicine.12-3-299
Clin Med June 2012
G Bothamley
Department of respiratory medicine, Homerton University Hospital
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M Lipman
Department of respiratory medicine, Royal Free Hospital
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
O M Kon
Department of respiratory medicine, St. Mary's Hospital
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Editor – We were concerned that a new treatment for tuberculosis (TB) was being advocated without the benefit of a randomised controlled trial (W Saeed, Clin Med February 2012 pp 40–1). The authors argue that cavitary pulmonary TB relapses following therapy in 21–25% of cases and that additional drugs (levofloxacin and amikacin) are required to prevent this. However, in a treatment trial of sputum smear-positive TB (a sine qua non for cavitary disease) with relatives supervising therapy in the follow-up phase, a standard six-month regimen with an initial phase of four drugs resulted in negative sputum cultures at 30 months in 94%.1 Furthermore, while levofloxacin has few adverse effects, irreversible hearing loss is a common finding in those treated with amikacin.2 Research itself is known to improve patient outcomes. Improved care rather than the addition of two further drugs to the standard treatment regimen for TB may have been responsible for the observed ‘complete bacteriological cure at three months and radiological cure at the end of six months’ that are reported in an unspecified number of patients from an, as yet unpublished, study.

  • © 2012 Royal College of Physicians

References

  1. ↵
    1. Nunn AJ,
    2. Jindani A,
    3. Enarson DA
    .for the Study A investigators Results at 30 months of a randomised trial of two 8 month regimens for the treatment of tuberculosis. Int J Tuberc Lung Dis 2011;15:741–5doi:10.5588/ijtld.10.0392
    OpenUrlPubMed
  2. ↵
    1. Sturdy A,
    2. Goodman A,
    3. Jose RJ,
    4. et al
    . Multidrug-resistant tuberculosis (MDR-TB) treatment in the UK: a study of injectable use and toxicity in practice. J Antimicrob Chmeother 2011;66:1815–20doi:10.1093/jac/dkr221
    OpenUrlAbstract/FREE Full Text
Back to top
Previous articleNext article

Article Tools

Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Citation Tools
Cavitating pulmonary tuberculosis: a global challenge
G Bothamley, M Lipman, O M Kon
Clinical Medicine Jun 2012, 12 (3) 299; DOI: 10.7861/clinmedicine.12-3-299

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Cavitating pulmonary tuberculosis: a global challenge
G Bothamley, M Lipman, O M Kon
Clinical Medicine Jun 2012, 12 (3) 299; DOI: 10.7861/clinmedicine.12-3-299
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • References
  • Info & Metrics

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • JAK-inhibition as a therapeutic strategy for refractory primary systemic vasculitides
  • Response
  • Functional disorders and chronic pain
Show more Letters to the editor

Similar Articles

Navigate this Journal

  • Journal Home
  • Current Issue
  • Ahead of Print
  • Archive

Related Links

  • ClinMed - Home
  • FHJ - Home
clinmedicine Footer Logo
  • Home
  • Journals
  • Contact us
  • Advertise
HighWire Press, Inc.

Follow Us:

  • Follow HighWire Origins on Twitter
  • Visit HighWire Origins on Facebook

Copyright © 2021 by the Royal College of Physicians